Dupilumab, a fully human monoclonal antibody targeting IL-4Rα, resulted in patients with severe, uncontrolled CRSwNP in significant symptom improvement and disease control in both phase III trials, leading to its approval as the first biologic medication for CRSwNP in 2019, next to its licenses for asthma bronchiale and atopic dermatitis [12]. This evidence concerns the gene IL4R and chronic rhinosinusitis with nasal polyps.